scispace - formally typeset
Search or ask a question
Institution

University of Modena and Reggio Emilia

EducationModena, Italy
About: University of Modena and Reggio Emilia is a education organization based out in Modena, Italy. It is known for research contribution in the topics: Population & Transplantation. The organization has 8179 authors who have published 22418 publications receiving 671337 citations. The organization is also known as: Università degli Studi di Modena e Reggio Emilia & Universita degli Studi di Modena e Reggio Emilia.


Papers
More filters
Journal ArticleDOI
TL;DR: Once-daily LABAs used both alone and in combination with long-acting muscarinic antagonists represent a promising advance in the treatment of COPD, and are likely to further improve outcomes for patients.
Abstract: Chronic obstructive pulmonary disease (COPD) is characterized by progressive airflow limitation and debilitating symptoms. For patients with moderate-to-severe COPD, long-acting bronchodilators are the mainstay of therapy; as symptoms progress, guidelines recommend combining bronchodilators from different classes to improve efficacy. Inhaled long-acting b2-agonists (LABAs) have been licensed for the treatment of COPD since the late 1990s and include formoterol and salmeterol. They improve lung function, symptoms of breathlessness and exercise limitation, health-related quality of life, and may reduce the rate of exacerbations, although not all patients achieve clinically meaningful improvements in symptoms or health related quality of life. In addition, LABAs have an acceptable safety profile, and are not associated with an increased risk of respiratory mortality, although adverse effects such as palpitations and tremor may limit the dose that can be tolerated. Formoterol and salmeterol have 12-hour durations of action; however, sustained bronchodilation is desirable in COPD. A LABA with a 24-hour duration of action could provide improvements in efficacy, compared with twicedaily LABAs, and the once-daily dosing regimen could help improve compliance. It is also desirable that a new LABA should demonstrate fast onset of action, and a safety profile at least comparable to existing LABAs. A number of novel LABAs with once-daily profiles are in development which may be judged against these criteria. Indacaterol, a LABA with a 24-hour duration of bronchodilation and fast onset of action, is the most advanced of these. Preliminary results from large clinical trials suggest indacaterol improves lung function compared with placebo and other long-acting bronchodilators. Other LABAs with a 24-hour duration of bronchodilation include carmoterol, vilanterol trifenatate and oldaterol, with early results indicating potential for once-daily dosing in humans. The introduction of once-daily LABAs also provides the opportunity to develop combination inhalers of two or more classes of once-daily long-acting bronchodilators, which may be advantageous for COPD patients through simplification of treatment regimens as well as improvements in efficacy. Once-daily LABAs used both alone and in combination with long-acting muscarinic antagonists represent a promising advance in the treatment of COPD, and are likely to further improve outcomes for patients.

130 citations

Journal ArticleDOI
19 Mar 2014-Neuron
TL;DR: It is demonstrated that DOR activation at the central terminals of myelinated mechanoreceptors depresses synaptic input to the spinal dorsal horn, via the inhibition of voltage-gated calcium channels, which reveals a molecular mechanism by which opioids modulate cutaneous mechanosensation.

130 citations

Journal ArticleDOI
TL;DR: This work outlines challenges that may vary across different models of cell therapy, including the following broad concepts: issues related to the sourcing of material, and Issues related to product manufacturing, shipping, storage and tracking, and standardization.

130 citations

Journal ArticleDOI
TL;DR: In both patients with asthma and those with COPD, fixed airflow obstruction is associated with increased lung function decline and frequency of exacerbations and the decline in lung function entails the specific pathological and clinical features of the underlying diseases.
Abstract: Background Both smokers and patients with asthma can experience fixed airflow obstruction, which is associated with distinctive patterns of airway pathology. The influence of fixed airflow obstruction on the prognosis of these patients is unknown. Objective We sought to investigate lung function decline and exacerbations in a 5-year prospective study of subjects with fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease (COPD). We also sought to explore correlations between functional, pathological, and clinical features. Methods Patients with fixed airflow obstruction due to asthma (n = 16) or COPD (n = 21) and a control group of asthmatic patients with fully reversible airflow obstruction (n = 15) were followed for 5 years. Results The rates of decline in FEV 1 were similar in patients with fixed airflow obstruction caused by asthma (−49.7 ± 10.6 mL/y) or COPD (−51.4 ± 9.8 mL/y) and were higher than in asthmatic patients with reversible airflow obstruction (−18.1 ± 10.1 mL/y, P P 1 decline in asthmatic patients with fixed airflow obstruction. By contrast, baseline sputum neutrophil counts, emphysema scores, comorbidities, and exacerbation frequency correlated directly and pulmonary diffusion capacity correlated inversely with the FEV 1 decline in patients with COPD. Conclusion In both patients with asthma and those with COPD, fixed airflow obstruction is associated with increased lung function decline and frequency of exacerbations. Nevertheless, the decline in lung function entails the specific pathological and clinical features of the underlying diseases.

130 citations

Journal ArticleDOI
10 Dec 2020-Gut
TL;DR: A large and updated meta-analysis of observational studies indicates that NAFLD is significantly associated with a~1.45-fold increased long-term risk of incident CKD stage ≥3.
Abstract: Objective Studies reported a significant association between non-alcoholic fatty liver disease (NAFLD) and increased risk of chronic kidney disease (CKD). However, whether this risk changes with increasing severity of NAFLD remains uncertain. We performed a meta-analysis of observational studies to quantify the magnitude of the association between NAFLD and risk of incident CKD. Design We systematically searched PubMed, Web of Science and Scopus from January 2000 to August 2020 using predefined keywords to identify observational studies with a follow-up duration of ≥1 year, in which NAFLD was diagnosed by blood biomarkers/scores, International Classification of Diseases codes, imaging techniques or biopsy. Data from selected studies were extracted, and meta-analysis was performed using random-effects modelling. Results 13 studies with 1 222 032 individuals (28.1% with NAFLD) and 33 840 cases of incident CKD stage ≥3 (defined as estimated glomerular filtration rate Conclusion This large and updated meta-analysis indicates that NAFLD is significantly associated with a~1.45-fold increased long-term risk of incident CKD stage ≥3. Further studies are needed to examine the association between the severity of NAFLD and risk of incident CKD.

129 citations


Authors

Showing all 8322 results

NameH-indexPapersCitations
Carlo M. Croce1981135189007
Gregory Y.H. Lip1693159171742
Geoffrey Burnstock141148899525
Peter M. Rothwell13477967382
Claudio Franceschi12085659868
Lorenzo Galluzzi11847771436
Leonardo M. Fabbri10956660838
David N. Reinhoudt107108248814
Stefano Pileri10063543369
Andrea Bizzeti99116846880
Brian K. Shoichet9828140313
Dante Gatteschi9772748729
Roberta Sessoli9542441458
Thomas A. Buchholz9349433409
Pier Luigi Zinzani9285735476
Network Information
Related Institutions (5)
University of Bologna
115.1K papers, 3.4M citations

97% related

Sapienza University of Rome
155.4K papers, 4.3M citations

97% related

University of Padua
114.8K papers, 3.6M citations

97% related

University of Milan
139.7K papers, 4.6M citations

95% related

Katholieke Universiteit Leuven
176.5K papers, 6.2M citations

93% related

Performance
Metrics
No. of papers from the Institution in previous years
YearPapers
202376
2022230
20212,354
20202,083
20191,633
20181,450